Here are the editors' top picks for the week ended Jan. 4.
Bristol-Myers, Celgene to face crowded cancer market together in $74B union
Bristol-Myers Squibb Co.'s $74 billion cash-and-stock acquisition of Celgene Corp., the first major deal in the new year, will be 12 times larger than any acquisition the New York pharmaceutical giant has made in the last decade.
US FDA shatters drug approval records in 2018
The U.S. Food and Drug Administration broke a number of records in 2018, most notably, shattering the agency's all-time high in approving first-of-their-kind therapies — clearing 59 last year.
Maine Gov. enacts Medicaid expansion plan on 1st day in office
Maine Gov. Janet Mills enacted the state's long-delayed Medicaid-expansion plan on the Democrat's first day in office. Expansion could increase coverage to more than 70,000 people.
Democratic coalition launches appeal to overturn ruling invalidating health law
A coalition of 17 Democratic attorneys general took the first step in launching an appeal aimed at overturning the decision by a federal judge in Texas who ruled in late 2018 that the entire Affordable Care Act was unconstitutional.
US FDA shutdown may last 'weeks'; commissioner warns of limited abilities
U.S. FDA Commissioner Scott Gottlieb warned drugmakers his agency was able to provide only limited services during the ongoing government shutdown, which the Republican Senate leader said could last for weeks.
Judge: Obama healthcare law remains in place during appeal
A federal district judge in Texas who said the entire Affordable Care Act was unconstitutional ruled in a new opinion that the law will remain in place while an appeal on his earlier decision is being pursued.
Judge sides with hospitals in HHS lawsuit challenging 340B drug-pricing changes
A federal district court judge said that the U.S. Department of Health and Human Services did not have the authority to reduce 340B reimbursements by nearly 30%. The judge requested additional material from both parties to help determine a remedy.